We recruited 115 patients with biopsy-proven NAFLD, 65 with NASH and 50 with simple steatosis, and 441 healthy control subjects and investigated 15 SNPs of PPARGC1A. This evidence concerns the gene PPARGC1A and metabolic dysfunction-associated steatotic liver disease.